Table 6.
Type of analyte | Category | Type of substrate | LOD (ng/mL) | MRPLi (ng/mL) | Ref. |
---|---|---|---|---|---|
CB | Beta-2 agonist | Au colloid | 35 | 0.2 | [153] |
SB | Beta-2 agonist | Au colloid | 765 | 20 | [153] |
TB | Beta-2 agonist | Au colloid | 55 | 20 | [153] |
PB | Diuretic and masking agent | Ag NPs | 1.2 × 103 | 200 | [157] |
AGI | Hormone and metabolic modulator | Au NPs | 85 | 20 | [159] |
AGI | Hormone and metabolic modulator | Au NPsc | 85 | 20 | [162] |
Ag NPsd | 5.1 | ||||
Ag NPse | 0.13 | ||||
17 β-Estradiol (E2) | Anabolic agent | Au NPsf | 0.65 × 10−3 | 2 | [164] |
rHuEPOa | Peptide hormone, growth factor, | Magnetic core Au NPs (Au@ iron oxide core shell) | 10−3h | 2 | [165] |
hCGb | Glycoprotein hormone | Ag NPs | 0.05–20 | 0.05 | [166] |
Propranolol | Beta-blocker | Ag NPs | 2.36 | 100 | [167] |
PB | Diuretic and masking agent | Ag NPsg | 51.3 | 200 | [163] |
Recombinant human erythropoietin.
Human chorionic gonadotropin (banned in men only).
Spherical shape with 20 nm in diameter.
Spherical shape with 50 nm in diameter.
Triangular shape.
36.7 ± 5.5 nm.
Star-shaped.
Nano molar (nM).
WADA general Minimum Required Performance Limit (MRPL) values.